Literature DB >> 14754447

Nicotine and nicotinic receptor involvement in neuropsychiatric disorders.

Paul Newhouse1, Abhay Singh, Alexandra Potter.   

Abstract

Advances in the understanding of the neurobiology of the nicotinic receptor have started to be matched by an appreciation of the potential role of these receptors in a variety of neuropsychiatric disorders. While alterations in nicotinic receptor number and/or function have been associated with such conditions as Alzheimer's disease for several years, there is increasing evidence that nicotinic receptor function may play a significant role in other disorders as well including schizophrenia, Parkinson's disease, anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Research in our laboratory and those of other investigators have utilized sophisticated psychopharmacological, cognitive, electrophysiological, neuroimaging and other techniques to assess the impact of nicotinic receptor modulation on the clinical expression of these disorders. This manuscript reviews data, both experimental and clinical, relating to the role of nicotine and/or nicotinic receptor function in a variety of neuropsychiatric disorders with the perspective of developing appropriate targets for therapeutic drug development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754447     DOI: 10.2174/1568026043451401

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  23 in total

1.  Long-term effects of chronic nicotine exposure on brain nicotinic receptors.

Authors:  Morgane Besson; Sylvie Granon; Monica Mameli-Engvall; Isabelle Cloëz-Tayarani; Nicolas Maubourguet; Anne Cormier; Pierre Cazala; Vincent David; Jean-Pierre Changeux; Philippe Faure
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 2.  Smoking and suicide: a brief overview.

Authors:  John R Hughes
Journal:  Drug Alcohol Depend       Date:  2008-08-03       Impact factor: 4.492

3.  Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice.

Authors:  J W Young; J M Meves; I S Tarantino; S Caldwell; M A Geyer
Journal:  Genes Brain Behav       Date:  2011-07-07       Impact factor: 3.449

4.  Nicotine deprivation influences P300 markers of cognitive control.

Authors:  David E Evans; Nathan D Maxfield; Kate Janse Van Rensburg; Jason A Oliver; Kade G Jentink; David J Drobes
Journal:  Neuropsychopharmacology       Date:  2013-06-28       Impact factor: 7.853

5.  Functional somato-dendritic alpha7-containing nicotinic acetylcholine receptors in the rat basolateral amygdala complex.

Authors:  Rebecca C Klein; Jerrel L Yakel
Journal:  J Physiol       Date:  2006-08-24       Impact factor: 5.182

Review 6.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

7.  CHRNA5 variants moderate the effect of nicotine deprivation on a neural index of cognitive control.

Authors:  D E Evans; D A MacQueen; K G Jentink; J Y Park; H-Y Lin; D J Drobes
Journal:  Genes Brain Behav       Date:  2014-07-23       Impact factor: 3.449

8.  In the shadow of a new smoke free policy: A discourse analysis of health care providers' engagement in tobacco control in community mental health.

Authors:  Joy L Johnson; Barbara M Moffat; Leslie A Malchy
Journal:  Int J Ment Health Syst       Date:  2010-07-28

9.  Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.

Authors:  Jared W Young; Jessica M Meves; Mark A Geyer
Journal:  Behav Brain Res       Date:  2012-11-29       Impact factor: 3.332

10.  Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons.

Authors:  Dustin W DuBois; Joanne C Damborsky; Annette S Fincher; Gerald D Frye; Ursula H Winzer-Serhan
Journal:  Life Sci       Date:  2013-01-24       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.